The ERIKA trial: still limited evidence on the efficacy of thromboprophylaxis after knee arthroscopy

Thromb Haemost 2016; 116(05): 1001
DOI: 10.1160/TH16-05-0396

Author Correspondence

Schattauer GmbH

Banne Nemeth

¹Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

²Department of Orthopedic Surgery, Leiden University Medical Center, Leiden, The Netherlands

,

Raymond A. van Adrichem

¹Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

²Department of Orthopedic Surgery, Leiden University Medical Center, Leiden, The Netherlands

,

Suzanne C. Cannegieter

¹Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

³Department of Thrombosis and Haemostasis, Leiden University Medical Center, Leiden, The Netherlands

References
1 Camporese G, Bernardi E, Noventa F. et al. Efficacy of Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA). A phase II, multicentre, double-blind, placebo-controlled randomised study. Thromb Haemost 2016; 116: 349-355.
2 Gaskill T, Pullen M, Bryant B. et al. The Prevalence of Symptomatic Deep Venous Thrombosis and Pulmonary Embolism After Anterior Cruciate Ligament Reconstruction. Am JSports Med 2015; 43: 2714-2719.
3 Krych AJ, Sousa PL, Morgan JA. et al. Incidence and Risk Factor Analysis of Symptomatic Venous Thromboembolism After Knee Arthroscopy. Arthroscopy 2015 Epub ahead of print.
4 Mauck KF, Froehling DA, Daniels PR. et al. Incidence of venous thromboembolism after elective knee arthroscopic surgery: a historical cohort study. JThrombHaemost 2013; 11: 1279-1286.